Overall Survival

Defined as the time from randomization until death due to any cause

Assessed for up to approximately 5 years

Minimal Residual Disease negativity rate

Minimal Residual Disease negativity rate per IMWG criteria as assessed via Next Generation Sequencing

12 months after randomization

Sustained MRD negativity rate

Sustained Minimal Residual Disease negativity rate per IMWG criteria as assessed via Next Generation Sequencing

24 months after randomization

Progression Free Survival

Progression Free Survival by investigator per IMWG response criteria

Assessed for up to approximately 5 years

Overall minimal residual disease negativity rate

Minimal residual disease negativity rate per IMWG criteria

Assessed for up to approximately 5 years

Duration of minimal residual disease negativity

Minimal residual disease negativity per IMWG criteria

Assessed for up to approximately 5 years

Sustained minimal residual disease negativity rate

Minimal residual disease negativity per IMWG criteria that has lasted a minimum of 12 months

Assessed for up to approximately 5 years

Complete response rate

Complete response rate by blinded independent central review and by investigator per IMWG criteria

Assessed for up to approximately 5 years

Duration of complete response

Duration of complete response by blinded independent central review and by investigator per IMWG criteria

Assessed for up to approximately 5 years

Frequency of adverse events

Adverse event as characterized by type, frequency, severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5, seriousness and relationship to the study intervention

Up to 90 days after last dose

Frequency of laboratory abnormalities

Assessed for up to approximately 5 years

Pre-dose concentrations of elranatamab

Pharmacokinetics of elranatamab (trough concentrations of elranatamab)

Assessed for up to approximately 5 years

Post-dose concentrations of elranatamab

Pharmacokinetics of elranatamab (Post-dose serum concentrations of elranatamab)"

Assessed for up to approximately 5 years

Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab

Immunogenicity of elranatamab

Assessed for up to approximately 5 years

Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30

Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms

Assessed for up to approximately 5 years

Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20

Higher scores on the functioning subscales (body image, future perspective) represent higher levels of functioning, whereas higher scores on the symptom subscales (disease symptoms, side effects) represent a greater presence of symptoms

Assessed for up to approximately 5 years

Progression Free Survival 2

Progression Free Survival to the date of second objective disease progression by investigator per IMWG response criteria

Assessed for up to approximately 5 years